News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Changing Top Trends in Health Economics and Operational Research

January 20, 2020
By Leela Barham
Article

ISPOR has published its third issue of the top trends in HEOR. Leela Barham takes a look at how the list has changed over time.

ISPOR has published its third issue of the top trends in HEOR. Leela Barham takes a look at how the list has changed over time.

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is the self-proclaimed leading professional society for health economics and outcomes research globally. ISPOR’s 20,000 members span the world and its leaders1 include experts from academia, industry, consultancy, as well as those working in health technology assessment (HTA) agencies.  

In 2018 ISPOR began to identify the top 10 trends in health economics and outcomes research (HEOR); its latest top 10 trends for 2020 is published this month. So what’s rising and what’s falling? 

Table 1: ISPORs top 10 trends in HEOR, 2018, 2019 and 2020

Source: Based upon ISPOR top 10 HEOR trends for 2018, 2019, and 2020.

 

Real-world evidence has emerged as the top issue for 2020 and was in the top 3 for 2019. Drug pricing is a consistent theme, moving from the number 1 slot in 2018 and 2019 but only to second position in 2020. Curative therapies have made a return to the top 10 in 2020, at number 3, after disappearing from 2019’s top 10, but being number 2 back in 2018.

What’s interesting to note too, aside from the top issues having some consistency, is how some topics have dropped off the chart. Issues including accelerated drug approvals, diagnostics, biosimilars, disruptive innovators, big data, value assessment frameworks, healthcare decision making for low-income countries and unhealthy behaviors are no longer explicitly named checked. 

Yet this is why it matters to recognize the linkages across the topics; precision medicine is linked to diagnostics, for example. Similarly, overall healthcare spending, a new topic for 2020, is linked to issues such as the use of biosimilars, which can come in at lower prices than their originator biologics (albeit recognizing that medicines spend is still only a small part of overall medicines spend). Plus, it’s hard to know if you’re doing a value-based contract unless you’ve agreed on what value is which is what value assessment frameworks try to do. 

It may also be partly to do with the evolution in terminology over time; this probably explains the move from mHealth to digital technologies for example. As long as the change is to help more clearly convey the concept, that’s all good. 

It’s likely, given the breadth and depth of ISPOR membership, that many of these top topics are exactly what payers want help on, so expect more from the ISPOR membership on how to respond to payer worries, which can also help companies to respond. 

And for those who (rightly) always ask about the patient, they are there too; real-world evidence does, after all, come from patients.

Leela Barham is a researcher and writer on health and pharmaceuticals from a health economic and policy perspective. 

1. www.ispor.org/about/our-leaders

Recent Videos
Arda Ural
Lynlee Brown
Arda Ural
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Related Content

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

Don Tracy, Associate Editor
May 13th 2025
Article

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.


Impact, Access, and Scale: The Potential of India’s Pharma Market

Impact, Access, and Scale: The Potential of India’s Pharma Market

Roshel Jayasundera;Joshua Siow;Bhavna Desai
May 8th 2025
Article

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.


Creating a Gray Zone in Payer Messaging: Outflanking Comparability

Creating a Gray Zone in Payer Messaging: Outflanking Comparability

Ira Studin, PhD
May 8th 2025
Article

The argument for weighing clinical points more heavily in the access equation.


Justin Holko

A Global Approach to Oncology: Q&A with Justin Holko

Mike Hollan
April 28th 2025
Article

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.


Bill Coyle

Predicting and Planning for Tariff Impacts: Q&A with Bill Coyle

Mike Hollan
April 25th 2025
Article

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.


Marcel Botha

The Risks and Opportunities of Tariffs: Q&A with Marcel Botha

Mike Hollan
April 25th 2025
Article

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve certain conditions.

Related Content

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

Don Tracy, Associate Editor
May 13th 2025
Article

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.


Impact, Access, and Scale: The Potential of India’s Pharma Market

Impact, Access, and Scale: The Potential of India’s Pharma Market

Roshel Jayasundera;Joshua Siow;Bhavna Desai
May 8th 2025
Article

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.


Creating a Gray Zone in Payer Messaging: Outflanking Comparability

Creating a Gray Zone in Payer Messaging: Outflanking Comparability

Ira Studin, PhD
May 8th 2025
Article

The argument for weighing clinical points more heavily in the access equation.


Justin Holko

A Global Approach to Oncology: Q&A with Justin Holko

Mike Hollan
April 28th 2025
Article

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.


Bill Coyle

Predicting and Planning for Tariff Impacts: Q&A with Bill Coyle

Mike Hollan
April 25th 2025
Article

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.


Marcel Botha

The Risks and Opportunities of Tariffs: Q&A with Marcel Botha

Mike Hollan
April 25th 2025
Article

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve certain conditions.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.